Form 4: Ultragenyx Director Deborah Dunsire Reports Stock and Option Awards

Director Deborah Dunsire reports the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Summary

• On June 18, 2024, Deborah Dunsire, a director of Ultragenyx Pharmaceutical Inc., reported the acquisition of 5,345 shares of common stock through restricted stock units (RSUs) and an option to purchase 9,900 shares of common stock.
• The RSUs were awarded under the company's 2023 Incentive Plan and will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• The stock option, with an exercise price of $37.42, also vests on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Following these transactions, Dunsire directly owns 25,075 shares of Ultragenyx Pharmaceutical Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option awards, which is generally a positive sign of aligning management interests with shareholders, but doesn't inherently indicate strong positive or negative sentiment.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs and stock options is contingent upon future events, specifically the company's next Annual Meeting of Stockholders or June 18, 2025, indicating a focus on long-term performance and alignment with shareholder interests.

Industry Context

Form 4 filings are routine disclosures that provide transparency into the transactions of company insiders, offering insights into their perspectives on the company's valuation and future prospects. These filings are closely monitored by investors seeking to understand management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the granting of RSUs and stock options to a director as a positive sign, aligning the director's interests with the company's long-term success.

Key Dates